Orano has appointed Frederic Desdouits as the Chief Executive Officer of its subsidiary Orano Med, a biotechnology company pioneering the development of targeted alpha therapies in oncology. Nicolas Maes, CEO of the Orano group, said, “The extensive experience of Frederic Desdouits in the pharmaceutical industry, particularly in the biotechnology sector, will be a valuable asset in accelerating the development of the clinical portfolio as well as the deployment of Orano Med’s industrial platf...